Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany.
Leukemia. 2013 Apr;27(4):762-72. doi: 10.1038/leu.2013.36. Epub 2013 Feb 6.
Waldenstrom's macroglobulinemia (WM) is very distinct from other indolent lymphoma subtypes: by definition it is accompanied by a monoclonal IgM gammopathy; it presents always with bone marrow infiltration and often with clinical symptoms such as neuropathy or hyperviscosity. These disease characteristics and the frequently advanced age of the WM patient pose a major challenge to the treating clinician even today. Recently, there has been not only substantial progress in our understanding of the biology of WM, but we have also significantly improved our tools to prognostify and to treat patients with this disease. This review summarizes our current knowledge about WM and aims at offering a guideline for the clinical management of patients with this lymphoma subtype, covering questions on how to manage diagnosis, prognostification and treatment based on the most recent data.
华氏巨球蛋白血症(WM)与其他惰性淋巴瘤亚型有很大的不同:根据定义,它伴随着单克隆 IgM 球蛋白血症;它总是伴有骨髓浸润,并且经常伴有神经病或高粘滞血症等临床症状。这些疾病特征以及 WM 患者通常年龄较大,即使在今天,也给治疗医生带来了巨大的挑战。最近,我们不仅在 WM 的生物学理解方面取得了实质性进展,而且还显著改进了我们用于预测和治疗这种疾病患者的工具。这篇综述总结了我们目前对 WM 的认识,并旨在为这种淋巴瘤亚型的患者的临床管理提供指导,涵盖了如何根据最新数据管理诊断、预后和治疗的问题。